The health start-up Mymee has acquired the Berlin-based MS digital platform, Breakthrough Health.
Following the acquisition, Mymee aims to gain deeper expertise in the needs of MS patients and scale the company’s personalised health platform and research.
MS affects an estimated 2.8 million people worldwide, with women four times more likely than men to develop the disease. In the US alone, MS and rheumatological autoimmune diseases like lupus, Sjögren’s syndrome and rheumatoid arthritis are estimated to affect 10 million people.
Mymee has invested in ‘n-of-1’ clinical research, focusing on individual case studies, to develop a support programme for people who struggle with persistent, unpredictable symptoms, including fatigue, brain fog and pain.
The company uses self-evidence or patient-reported data to help people identify personal disease triggers, reduce symptoms and improve overall quality of life.
“Helping those with highly variable autoimmune diseases involves both disease-specific experience and a personalised approach that accounts for the detailed nuances of each person’s case,” said Mymee founder, Mette Dyhrberg.
“The addition of Breakthrough Health’s innovation and mission-driven product, technology and growth leadership empowers us to scale and continuously improve our personalisation capabilities and strengthens our support for individuals living with MS as well as those with long Covid who share some symptoms associated with neurological autoimmune diseases.”
Breakthrough Health is also the creator of the MS mobile app Emilyn. The company’s founding team, Bazil Azmil, Stefano Palazzo and Rachel Reichel, will join the Mymee leadership team as head of growth, CTO and VP of product, respectively, effective immediately.
“What we have found in supporting Emilyn’s MS community over the past four years was that most members were managing significant symptoms between neurologist visits but had no power to predict or prevent them,” said Bazil Azmil, co-founder and former CEO at Breakthrough Health.
“Now our determination to find a solution led us to Mymee with their systems-based approach to connecting the dots between autoimmune symptoms and triggers.”
